← boardnext 2027-01
ELDN
Eledon Pharmaceuticalsdistress 4/10 · elevated risk$3.69-1%today-15% from 52w high
Nephrology 1
Lead: Kidney Transplant Rejection · target CD40L
Revenue
pre-revenue
Liquidity
$111M
Runway
1.6 yrs
Shares 1y
+29%
Price & events
+65.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-3.8%
1W
-6.5%
1M
+2.9%
3M
+72.7%
6M
-3.0%
1Y
+18.1%
2Y
-43.6%
5Y
-74.7%
All
Overview
- Market Cap
- $285.21M
- Volume
- 120.42K
- 52 Week Range
- $1.39 – $4.36
- Total Shares
- 77.19M
- Float Shares
- 69.93M
- Short %
- 10.15%
- % Held by Insiders
- 1.09%
- % Held by Institutions
- 59.35%
- RVOL
- 0.08x
- Beta
- 0.96
Pipeline stages · 1 programs
AT-1501, Tacrolimus
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 1/2 | AT-1501 | Prevention of Rejection in Kidney Transplant | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-01-15 | Phase 2 | AT-1501, Tacrolimus | Kidney Transplant Rejection | — | enrolling by invitation |
| 2025-09-11 | Phase 2 | AT-1501, Tacrolimus | Kidney Transplant Rejection | 127 | completed |
Catalyst news & presentations · 3
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- November 06, 2025readoutPhase 2tegoprubart · Phase 2 BESTOW trial results presented at ASN Kidney Week 2025SEC 8-K
- October 29, 2024conferencedata presentationsecondarytegoprubart · Oral presentation at IPITA/HSCI/Breakthrough T1D Stem Cells Summit of initial data from investigator-initiated trial of tegoprubart for islet transplantation.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+144% upside) · 5 analysts
- 2026-07-21Rodman & RenshawBuy
- 2025-11-18GuggenheimBuy
- 2025-09-02HC Wainwright & Co.Buy
- 2025-07-25Craig-HallumBuy
- 2024-11-20HC Wainwright & Co.Buy
Competitors — CD40L
- none identified
Recent news
- 2026-07-21ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
- 2026-07-20LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
- 2026-07-17Sudanese and Egyptian Filmmakers Win PixVerse Special Prize at UN AI for Good Film Festival - Business Wire
- 2026-07-13PixVerse Closes Series C Extension, Bringing Total to USD 439 Million, and Announces Expansion Into Interactive Entertainment - Business Wire
- 2026-07-06Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer - Business Wire
- 2026-07-05Eledon Pharmaceuticals (ELDN) Edges Higher as Stock Approaches Key Resistance at $4.15 - Leading Diagonal - dars.gov.et
- 2026-06-29Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
- 2026-06-29Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.